Related references
Note: Only part of the references are listed.Local tolerance and systemic toxicity of single and repeated intramuscular administrations of two different formulations of the RTS,S malaria candidate vaccine in rabbits
Lawrence Segal et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2015)
Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells
Arnaud M. Didierlaurent et al.
JOURNAL OF IMMUNOLOGY (2014)
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
Wim H. J. Kruit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
WT1 Promotes Cell Proliferation in Non-Small Cell Lung Cancer Cell Lines Through Up-Regulating Cyclin D1 and p-pRb In Vitro and In Vivo
Caihua Xu et al.
PLOS ONE (2013)
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines
Marijo Bilusic et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Erika Hamilton et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Testicular Development in Cynomolgus Monkeys
Emiko Haruyama et al.
TOXICOLOGIC PATHOLOGY (2012)
Assessment of Circulating Hormones in Regulatory Toxicity Studies II. Male Reproductive Hormones
Robert E. Chapin et al.
TOXICOLOGIC PATHOLOGY (2012)
Study designs for the nonclinical safety testing of new vaccine products
Roy Forster
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2012)
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity
Sandra Morel et al.
VACCINE (2011)
Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
Genevieve M. Weir et al.
Cancers (2011)
Vaccines and Immunotherapeutics for the Treatment of Malignant Disease
Joel F. Aldrich et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua D. Brody et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A simple orchidometric method for the preliminary assessment of maturity status in male cynomolgus monkeys (Macaca fascicularis) used for nonclinical safety studies
Warren W. Ku et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2010)
Histopathological lesions following intramuscular administration of saline in laboratory rodents and rabbits
Celine Thuilliez et al.
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY (2009)
AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
Arnaud M. Didierlaurent et al.
JOURNAL OF IMMUNOLOGY (2009)
Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder
Zhaoli Lane et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
Gregory E. D. Mullen et al.
PLOS ONE (2008)
Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909:: Safety data and interferon-inducible protein-10 kinetics for humans and macaques
V. Ann Stewart et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate
Todd Sheridan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
Danila Valmori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer
Mirjam. T. Epping et al.
CANCER RESEARCH (2006)
Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model
S Pilon-Thomas et al.
JOURNAL OF IMMUNOTHERAPY (2006)
The human tumor antigen repressor of retinoic acid PRAME is a dominant receptor signaling
MT Epping et al.
CELL (2005)
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine
CL Cooper et al.
VACCINE (2004)
Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-Class CpG oligodeoxynucleotide TLR9 agonist
AM Krieg et al.
JOURNAL OF IMMUNOTHERAPY (2004)
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults:: A double-blind phase I/II study
CL Cooper et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
CpG DNA induces stronger immune responses with less toxicity than other adjuvants
RD Weeratna et al.
VACCINE (2000)
Share Paper
